Literature DB >> 18266273

Cellular uptake of C4b-binding protein is mediated by heparan sulfate proteoglycans and CD91/LDL receptor-related protein.

Patricia P Spijkers1, Cécile V Denis, Anna M Blom, Peter J Lenting.   

Abstract

C4b-binding protein (C4BP) is a protein acting as a complement inhibitor and a carrier protein for anticoagulant protein S. Previously, we reported that the in vivo clearance of C4BP involves CD91, and that a CD91-interactive site overlaps the heparin-binding site within C4BP alpha-chains 26. Here, we investigated the C4BP-CD91 interaction in more detail. Binding of C4BP to CD91 was unaffected by protein S, which associates with C4BP beta-chain. Second, mutagenesis of cationic residues within C4BP alpha-chains impaired CD91 binding, reducing the affinity of triple mutant C4BPalpha/R39Q-R64Q-R66Q by 20-fold (Kd= 10 nM versus 214 nM for wild-type and mutant C4BP, respectively). Accordingly, intracellular degradation of this mutant by CD91-expressing cells was reduced to levels of CD91-deficient cells. Moreover, C4BPalpha/R39Q-R64Q-R66Q displayed a 3-fold prolonged survival compared to normal C4BP in in vivo clearance experiments. Since these residues also contribute to heparin binding, we explored the role of heparin-sulfate proteoglycans (HSPG) in the endocytosis of C4BP. The absence of HSPG was associated with a near complete absence of cell binding and intracellular degradation of C4BP. Apparently, the cellular uptake of C4BP depends on both HSPG and CD91, involving interactions with positively charged residues within C4BP alpha-chain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18266273     DOI: 10.1002/eji.200737722

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Re-examination of CD91 function in GRP94 (glycoprotein 96) surface binding, uptake, and peptide cross-presentation.

Authors:  Angela R Jockheck-Clark; Edith V Bowers; Mariam B Totonchy; Julie Neubauer; Salvatore V Pizzo; Christopher V Nicchitta
Journal:  J Immunol       Date:  2010-11-03       Impact factor: 5.422

2.  Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation.

Authors:  Panisadee Avirutnan; Richard E Hauhart; Pawit Somnuke; Anna M Blom; Michael S Diamond; John P Atkinson
Journal:  J Immunol       Date:  2011-06-03       Impact factor: 5.422

3.  Cell surface heparan sulfate proteoglycans are involved in the extracellular Hsp90-stimulated migration and invasion of cancer cells.

Authors:  Anastasiya V Snigireva; Veronika V Vrublevskaya; Yuri Y Skarga; Oleg S Morenkov
Journal:  Cell Stress Chaperones       Date:  2019-01-18       Impact factor: 3.667

4.  C4b-binding Protein Protects β-Cells from Islet Amyloid Polypeptide-induced Cytotoxicity.

Authors:  Jonatan Sjölander; Elin Byman; Klaudia Kulak; Sara C Nilsson; Enming Zhang; Ulrika Krus; Gunilla T Westermark; Petter Storm; Ben C King; Erik Renström; Anna M Blom
Journal:  J Biol Chem       Date:  2016-08-26       Impact factor: 5.157

5.  Low-density lipoprotein receptor-related protein 1 is a novel modulator of radial glia stem cell proliferation, survival, and differentiation.

Authors:  Dina Safina; Frederik Schlitt; Ramona Romeo; Thorsten Pflanzner; Claus U Pietrzik; Vasanthy Narayanaswami; Frank Edenhofer; Andreas Faissner
Journal:  Glia       Date:  2016-06-03       Impact factor: 7.452

6.  Cell surface heparan sulfate proteoglycans are involved in the binding of Hsp90α and Hsp90β to the cell plasma membrane.

Authors:  Anastasiya V Snigireva; Veronika V Vrublevskaya; Vladimir N Afanasyev; Oleg S Morenkov
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 7.  The Endothelial Glycocalyx as a Target of Ischemia and Reperfusion Injury in Kidney Transplantation-Where Have We Gone So Far?

Authors:  Anila Duni; Vassilios Liakopoulos; Vasileios Koutlas; Charalampos Pappas; Michalis Mitsis; Evangelia Dounousi
Journal:  Int J Mol Sci       Date:  2021-02-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.